Detalles de la búsqueda
1.
Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
Am J Hematol
; 99(6): 1031-1039, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429922
2.
Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
Am J Hematol
; 98(9): 1415-1424, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37401738
3.
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
Ann Hematol
; 101(3): 533-539, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981144
4.
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.
Br J Haematol
; 197(1): e12-e15, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931307
5.
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
Br J Clin Pharmacol
; 82(4): 994-1001, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27276421
6.
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
Blood Adv
; 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640437
7.
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Blood Adv
; 7(4): 611-619, 2023 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018224
8.
Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
Lancet Neurol
; 18(7): 631-642, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31202468
9.
Randomized, Blinded, Placebo- and Positive-Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects.
Clin Pharmacol Drug Dev
; 7(1): 22-32, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28394491
10.
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans.
Clin Pharmacol Ther
; 79(3): 255-62, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16513449
11.
The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction.
Biochem Pharmacol
; 71(3): 366-76, 2006 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-16332358
12.
Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.
Drugs Aging
; 32(12): 1029-43, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26508138
13.
Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia.
Br J Pharmacol
; 140(6): 1146-54, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14559859
14.
5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide.
Br J Pharmacol
; 141(3): 407-14, 2004 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-14718257
15.
Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators.
Br J Pharmacol
; 137(6): 881-91, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12411420
16.
Signal transduction pathways implicated in the decrease in CYP1A1, 1A2 and 3A6 activity produced by serum from rabbits and humans with an inflammatory reaction.
Biochem Pharmacol
; 68(3): 573-82, 2004 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15242823
17.
The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression.
Expert Opin Drug Metab Toxicol
; 7(9): 1083-100, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21619472
18.
Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration.
J Clin Pharmacol
; 50(5): 544-53, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20051587
19.
Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver.
Drug Metab Dispos
; 35(5): 765-71, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17303624
20.
Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6.
Drug Metab Dispos
; 34(1): 27-35, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16204464